x

  • Next Post
  • Previous Post

x

David Dornan, PhD

/ Uncategorized

Share the Post

About the Author

Related Posts

Phase 2 study of nab-sirolimus in patients with well-differentiated and advanced/metastatic neuroendocrine tumors of the gastrointestinal tract, lung, or pancreas
AADi Announces Licensing Agreement with Celgene for Nanotechnology-Based Drug Candidate
Analysis of inactivating alterations in TSC1 and TSC2 in advanced genitourinary (GU) cancers from a real-world patient population in the Foundation Medicine genomic database
cache
ABI-009 (nab-sirolimus) in Advanced Malignant Perivascular Epithelioid Cell Tumors (PEComa): Preliminary Efficacy, Safety, and Mutational Status from AMPECT, an Open-label Phase II Registration Trial
Phase 2, Multicenter Open-label Basket Trial of nab-Sirolimus for Patients With Inactivating Alterations in TSC1 or TSC2 (PRECISION I)
Aadi Bioscience Appoints Brendan Delaney as Chief Operating Officer
Aadi Bioscience Announces Closing of Merger with Aerpio Pharmaceuticals and $155M Private Placement

Comments

Comments are closed.

  • Next Post
  • Previous Post